20-SEP-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

72% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2026
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2026
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1564 827 53% 1147 -416 1144 -420
ERLYTX 76 57 75% 79 3 75 -1
GI 479 117 24% 162 -316 167 -312
GU 450 268 60% 371 -78 372 -78
GYN 57 0 0% 0 -57 0 -57
LEUK 150 120 80% 166 16 162 12
LUNG 524 149 28% 206 -317 199 -325
LYMPH 172 323 188% 448 276 422 250
MELAN 55 5 9% 6 -48 7 -48
MMYEL 147 86 59% 119 -27 110 -37
MULT 0 32   44 44 51 51
OTHER 0 33   45 45 47 47
PREV 0 0   0 0 0 0
SXQOL 0 0   0 0 0 0
Total 3674 2017   2793 -875 2756 -918

20-SEP-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

72% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2026
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2026
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 43 0 0% 0 -43 0 -43
CCD 0 162   224 224 203 203
ERLYTX 0 1   1 1 2 2
GI 0 1   1 1 1 1
GU 0 9   12 12 9 9
LEUK 69 444 643% 616 547 607 538
LUNG 43 254 591% 352 309 367 324
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 14   19 19 15 15
PEOLC 0 20   27 27 73 73
PREV 0 159   220 220 225 225
SURV 0 0   0 0 0 0
SXQOL 888 475 53% 659 -228 649 -239
Total 1188 1539   2131 944 2151 963

20-SEP-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

72% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2026
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2026
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1607 827 51% 1147 -459 1144 -463
CCD 0 162   224 224 203 203
ERLYTX 76 58 76% 80 4 77 1
GI 479 118 25% 163 -315 168 -311
GU 450 277 62% 384 -65 381 -69
GYN 57 0 0% 0 -57 0 -57
LEUK 219 564 258% 782 563 769 550
LUNG 567 403 71% 559 -7 566 -1
LYMPH 225 323 144% 448 223 422 197
MELAN 55 5 9% 6 -48 7 -48
MMYEL 239 86 36% 119 -119 110 -129
MULT 0 32   44 44 51 51
OTHER 0 47   65 65 62 62
PEOLC 0 20   27 27 73 73
PREV 0 159   220 220 225 225
SURV 0 0   0 0 0 0
SXQOL 888 475 53% 659 -228 649 -239
Total 4862 3556   4927 72 4907 45

20-SEP-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

72% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2026
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2026
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1018 498 49% 691 -326 701 -317
ERLYTX 76 41 54% 56 -19 53 -23
GI 421 93 22% 129 -291 126 -295
GU 375 196 52% 272 -102 277 -98
GYN 57 0 0% 0 -57 0 -57
LEUK 122 76 62% 105 -16 98 -24
LUNG 441 101 23% 140 -300 127 -314
LYMPH 129 211 164% 292 163 274 145
MELAN 55 5 9% 6 -48 7 -48
MMYEL 85 47 55% 65 -19 60 -25
MULT 0 13   18 18 19 19
OTHER 0 33   45 45 47 47
PREV 0 0   0 0 0 0
SXQOL 0 0   0 0 0 0
Total 2779 1314   1819 -952 1789 -990

20-SEP-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

72% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2026
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2026
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 16 0 0% 0 -16 0 -16
CCD 0 118   163 163 152 152
ERLYTX 0 1   1 1 2 2
GI 0 1   1 1 1 1
GU 0 9   12 12 9 9
LEUK 69 177 257% 245 176 245 176
LUNG 30 149 497% 206 176 223 193
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 14   19 19 15 15
PEOLC 0 18   24 24 59 59
PREV 0 158   219 219 224 224
SURV 0 0   0 0 0 0
SXQOL 750 354 47% 491 -258 472 -278
Total 1010 999   1381 372 1402 392

20-SEP-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

72% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2026
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2026
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1034 498 48% 691 -342 701 -333
CCD 0 118   163 163 152 152
ERLYTX 76 42 55% 58 -17 55 -21
GI 421 94 22% 130 -290 127 -294
GU 375 205 55% 284 -90 286 -89
GYN 57 0 0% 0 -57 0 -57
LEUK 191 253 132% 351 160 343 152
LUNG 471 250 53% 346 -124 350 -121
LYMPH 182 211 116% 292 110 274 92
MELAN 55 5 9% 6 -48 7 -48
MMYEL 177 47 27% 65 -111 60 -117
MULT 0 13   18 18 19 19
OTHER 0 47   65 65 62 62
PEOLC 0 18   24 24 59 59
PREV 0 158   219 219 224 224
SURV 0 0   0 0 0 0
SXQOL 750 354 47% 491 -258 472 -278
Total 3789 2313   3203 -578 3191 -598

20-SEP-2026 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

72% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2026
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2026
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 65 827 1272% 1147 1082 1144 1079
CCD 0 162   224 224 203 203
ERLYTX 0 1   1 1 2 2
GI 81 56 69% 77 -3 85 4
GU 215 129 60% 179 -35 189 -26
LEUK 0 38   52 52 54 54
LUNG 53 20 38% 27 -25 36 -17
LYMPH 7 63 900% 87 80 84 77
MELAN 0 5   6 6 5 5
MMYEL 0 67   92 92 88 88
OTHER 0 8   11 11 16 16
PEOLC 0 20   27 27 73 73
PREV 0 159   220 220 225 225
SURV 0 0   0 0 0 0
SXQOL 880 475 54% 659 -220 649 -231
Total 1301 2030   2809 1512 2853 1552

20-SEP-2026 6:11

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm. Phase Study Stat
Center		 Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure
BREAST II NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG 13APR2017:00:00:00   7     Dec-2022 Temp Close
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1     May-2022 Temp Close
  III A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib ALLIANCE 06JAN2021:00:00:00   55   0.0  
    A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab ALLIANCE 03MAY2023:00:00:00   66   2.5  
    A012303 Breast, HER2+, Shortened Adj ALLIANCE 25JUL2025:00:00:00   5   0.7  
    NRGBR009 Breast, EarlyStg, Adjuvant Chemo NRG 31AUG2023:00:00:00   49   2.0  
    S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva SWOG 30OCT2023:00:00:00 34 414 960 12.8 Mar-2030
    S2212 Breast, TNBC, Neoadj Chemo + Pembro SWOG 21JUL2023:00:00:00 37 1682 2400 72.0 Jun-2027
    S2511 Brst, de novo StgIV oligo, locoreg tx vs SOC SWOG 18AUG2026:00:00:00 1 0 534    
CCD III A232402CD CCD, Dose Mod Algorithm for FOLFOX ALLIANCE 06JAN2026:00:00:00   2   0.3  
    S1703 Met Breast, STM-monitoring v Usual Care SWOG 16JUL2018:00:00:00 98 476 498 3.8 Feb-2027
    S2417CD Colrec Surv, Follow-up w/ CTAC site SWOG 04AUG2025:00:00:00 13 126 654 13.0 Jan-2030
    S2424CD A-PACT vs SOC for GOC communication SWOG 01JUN2026:00:00:00 3 4 1000 1.1 > 15 Yrs
  OTHER A231602C Blood Cancer, Assess Financial Difficulty ALLIANCE 15MAR2019:00:00:00   4     Feb-2021 Temp Close
    ACCL16N1 Guideline Consistent Treatment AYA ALL COG 18DEC2017:00:00:00   54     Aug-2022 Temp Close
    EAQ222CD CostCOM, Cancer Patients, OOP Cost Com ECOG-ACRIN 29FEB2024:00:00:00   45   1.2  
ERLYTX II 21CTP.HN01 HN, Recur/Met, Amivantamab + Chemo SWOG 05MAR2026:00:00:00 6 9 50 1.5 Dec-2028
    A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 28AUG2015:00:00:00   9   0.0  
    SN2426 cSCC, IC Met/Inop, Amivantamab v Cetuximab SWOG 28JAN2026:00:00:00   11 86   Aug-2026 Temp Close
  II-III S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo SWOG 02DEC2021:00:00:00 57 167 189 3.5 Mar-2027
  III AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult COG 08MAY2017:00:00:00   5   0.2  
    AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo COG 30JUL2018:00:00:00   5     Temp Close
    EA7211 Sarc, Hi-Risk RetroPeritoneal, Neo+Sur ECOG-ACRIN 13JUN2023:00:00:00   2   0.3  
    S2505 Sarcoma, Stg II-IIIB, Surg + Short vs Std RT SWOG 06JUL2026:00:00:00 2 0 296    
  OTHER EAY191 ComboMATCH ECOG-ACRIN 06MAR2023:00:00:00   22   0.2  
GI II CCTGNE1 Midgut NET, Unresect, 177 Lut vs Ever CCTG 05JUN2023:00:00:00   9   0.3  
    EA2192 Panc, APOLLO ECOG-ACRIN 29APR2021:00:00:00   7   0.2  
    S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs SWOG 14OCT2021:11:13:50 59 107 154 2.8 Jan-2028
  II-III EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab ECOG-ACRIN 17JAN2019:00:00:00   6   0.0  
    EA2234 Gastric, all stg, Pac+Sys vs Sys ECOG-ACRIN 19AUG2025:00:00:00   1   0.2  
    NRGGI008 Colon, Stg III, Adj Chemo NRG 10MAR2022:00:00:00   77   3.2  
    S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo SWOG 06MAY2024:00:00:00 28 117 224 5.0 Jun-2028
  III A022101 Colorectal, Metastatic, Ablative Tx ALLIANCE 10JAN2023:00:00:00   1   0.0  
    A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo ALLIANCE 11JAN2023:00:00:00   42   0.8  
    CCTGCO32 Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad CCTG 29FEB2024:00:00:00   16   0.8  
    EA2222 Colorectal, Stg II-III, Hep Art Infusion ECOG-ACRIN 19OCT2023:00:00:00   10   0.5  
    S2433 PANC, KRAS WT, Met, SOC Chemo +/- Panitumumab SWOG 26DEC2025:00:00:00 8 1 94 0.2 > 15 Yrs
  OTHER A212101 Colorectal, New Dx. Gen Testing ALLIANCE 05MAR2026:00:00:00   1   0.2  
GU II A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) ALLIANCE 12APR2019:00:00:00   30   0.3  
    A032102 Prostate, All Stg, Precision Diagnostics ALLIANCE 11OCT2024:00:00:00   4   0.3  
    NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy NRG 30JUN2022:00:00:00   12   0.3  
    S2210 Pros, High Risk, BRCA, Neoadj Carbo SWOG 14AUG2023:00:00:00 37 6 44 0.0 > 15 Yrs
    S2427 Blad, MIBC, RT + Pembrolizumab SWOG 04SEP2025:00:00:00 12 46 111 6.3 Jul-2027
  II-III A032103 Urothelial, All Stg, MRD-Based Adj Tx ALLIANCE 09JAN2024:00:00:00   51   2.2  
    EA8192 Blad, High Grade UTUC, Durv + Chemo ECOG-ACRIN 06MAY2021:00:00:00   7   0.0  
  III A032201 Renal Cell, High-Risk, Pembro+Tiv ALLIANCE 05FEB2025:00:00:00   19   0.8  
    A032302 Prostate, Cast-Sens, Docetaxel ALLIANCE 25SEP2025:00:00:00   5   0.7  
    A032303 Bladder, High Grade, Gem+BCG vs BCG ALLIANCE 05JUN2025:00:00:00   8   0.8  
    A032304 Prostate, Meta CRPC w/Lu, Radioligand Effic ALLIANCE 09DEC2025:00:00:00   2   0.3  
    CCTG-PR24 Prostate, Unfav, Stereo vs Brachy CCTG 11MAR2024:00:00:00   7   1.0  
    CCTG-PR26 Prostate, Cast Sensitive, Docetax CCTG 30JAN2025:00:00:00   3   0.3  
    EA8191 Pros, Local vs Systemic Thrpy ECOG-ACRIN 08OCT2020:00:00:00   69   0.5  
    EA8231 Urothelial, Anti-PD(L)1, Pembro+Sac ECOG-ACRIN 23OCT2025:00:00:00   1   0.2  
    NRG-GU015 Bladder, Muscle Invasive, Rad+Chem NRG 14AUG2025:00:00:00   1   0.2  
    NRGGU013 Prostate, High-Risk, Five Fraction Radiation NRG 13NOV2023:00:00:00   22   1.2  
    S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum SWOG 17SEP2018:00:00:00 96 1051 1273 7.3 Mar-2029
    S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only SWOG 16NOV2020:00:00:00 70 161 336 2.3 Nov-2032
    S2312 Pros, MCRPC, Cab +/- Carb SWOG 03SEP2024:00:00:00 24 71 500 4.3 Nov-2034
    S2419 Renal, adv clear cell, IO +/- Biotx, BIOFRONT SWOG 22APR2026:00:00:00 4 27 718 5.5 Mar-2037
LEUK II 21CTP.LEUK01 ALL, Ph+, Asciminib, Dasatinib and Prednisone SWOG 11DEC2025:00:00:00 9 7 55 1.2 Feb-2030
    A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat ALLIANCE 16NOV2018:00:00:00   7   0.3  
    EA9213 T-ALL, dara-hyal for chemo refractory MRD ECOG-ACRIN 16JUN2022:00:00:00   4   0.2  
    MM1OA-EA02 MyeloMATCH: AML, New Dx, Ven+HMA ECOG-ACRIN 06JUN2024:00:00:00   19   0.5  
    MM1OA-S03 AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena SWOG 01APR2025:00:00:00 17 28 102 3.3 Jul-2028
    MM1OA-S04 MyeloMATCH: AML, ASTX727 + Ven (28D v 14D) SWOG 22JUL2026:00:00:00 1 0 126    
    MM1YA-CTG01 MyeloMATCH: AML, New Dx w/ Int Risk, Ven+Chem CCTG 18JUL2024:00:00:00   14   1.0  
    MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental SWOG 16MAY2024:00:00:00 28 88 335 4.3 May-2031
  III A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo ALLIANCE 01JUN2017:00:00:00   44   0.0  
    S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O SWOG 14DEC2020:00:00:00 69 209 247 5.2 Apr-2027
    S2504 Richter Trans., Untreated, R-CHOP +/- Pirto SWOG 01JUN2026:00:00:00 3 1 102 0.3 > 15 Yrs
  OTHER MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials SWOG 16MAY2024:00:00:00 28 1306   52.2  
LUNG II EA5162 NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 ECOG-ACRIN 05APR2018:00:00:00   4   0.0  
    S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu SWOG 03APR2023:00:00:00 41 28 44 0.7 Aug-2028
    S1900J MET Amplification: Amivantamab Hyaluronidase SWOG 27SEP2024:10:59:58 23 4 88 0.0 > 15 Yrs
    S1900K MET Exon 14: Tepotinib +/- Ramucirumab SWOG 18DEC2023:00:00:00 33 30 56 1.0 Oct-2028
    S1900N AGAs: SG alone, I alone, or SG + I SWOG 03AUG2026:00:00:00 1 0 117    
    S2409 ESCLC, Durvalumab +/- Biomarker Directed Tx SWOG 08SEP2025:00:00:00 12 17 900 2.3 > 15 Yrs
  II-III S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab SWOG 28APR2025:10:50:48 16 136 378 10.8 Jul-2028
  III A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO ALLIANCE 03JUN2020:00:00:00   110   0.8  
    EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 ECOG-ACRIN 22OCT2020:00:00:00   26   0.0  
    EA5221 Lung, Advanced NSCLC, ChemoImmuno/Immuno ECOG-ACRIN 15FEB2024:00:00:00   6   0.3  
    NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo NRG 10MAY2023:00:00:00   5   0.0  
    S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance SWOG 14MAR2025:00:00:00 18 14 306 1.2 > 15 Yrs
  OTHER LUNGMAP NSCLC, Adv, Master SWOG 28JAN2019:00:00:00 91 4111   27.7  
LYMPH II A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P ALLIANCE 30JUL2021:00:00:00   19   0.0  
    EA4231 Lymph, DL B-Cell, Ven+Ib+Pred+Ob+Rev ECOG-ACRIN 24JUN2025:00:00:00   1   0.2  
    S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation SWOG 23FEB2023:11:55:36 42 250 396 8.5 Feb-2028
    S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa SWOG 30JUN2023:11:49:39 38 41 173 0.3 > 15 Yrs
    S2506 NHL, R/R MZL, Mozun +/- Zanu or Pola SWOG 18AUG2026:00:00:00 1 0 138    
  III A042302 CLL/SLL, Untreated Older, Zan+Son ALLIANCE 06MAR2026:00:00:00   11   1.8  
    A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub ALLIANCE 08SEP2023:00:00:00   38   1.0  
    AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy COG 28APR2023:00:00:00   115   4.0  
    EA4232 Lymph, Peri T Cell, Auto Stem ECOG-ACRIN 30JAN2025:00:00:00   2   0.0  
    S2308 FL, LTB, Mosunetuzumab vs Rituximab SWOG 01AUG2024:00:00:00 25 423 600 24.0 Apr-2027
MELAN III EA6244 Melanoma, Naive Primary, Mgmt of Tx ECOG-ACRIN 12MAR2026:00:00:00   5   0.8  
MMYEL II A062102 MMYEL, All Stg, Iberdomide Tx ALLIANCE 04APR2024:00:00:00   1   0.2  
    EAA173 MYEL, SMM, Rd +/- Daratumumab ECOG-ACRIN 30APR2019:00:00:00   45   0.7  
    S2005 WM, Prev. Untreated, I/R or Z v V/R SWOG 24JUN2021:00:00:00 62 40 92 3.0 Feb-2028
  III EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) ECOG-ACRIN 27OCT2020:00:00:00   50   0.5  
    S1803 MM, Maintenance, Len vs Len/Dara SWOG 27JUN2019:00:00:00 86 1338 1100 0.0 000-0000
    S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D SWOG 30MAY2023:00:00:00 39 146 510 4.5 May-2033
    S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT SWOG 01DEC2023:00:00:00 33 52 142 2.2 Feb-2030
MULT II S2101 Melan or HNSCC, Adv, Cabo + Nivo SWOG 14OCT2022:10:48:23 47 108 220 4.5 Sep-2028
OTHER II A092105 Nasopharyngeal, Adv, Niv/Ip +- Cab ALLIANCE 18SEP2023:00:00:00   2   0.2  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   22   0.0  
    EA3191 HN, High Risk HNSCC, Adj +/- Pembro ECOG-ACRIN 08JAN2021:00:00:00   15   0.3  
    NRG-HN015 ¿¿SquaCell HN, Rec/Enriched, NeoVsChemo¿ NRG 12JAN2026:00:00:00   1   0.2  
    NRGGY032 Endo, ErlyStg Pole/p53, Adj Tx NRG 16APR2024:00:00:00   2   0.0  
    NRGHN010 HER2+ SGC, T-DM1 vs TH NRG 30SEP2022:00:00:00   4   0.0  
  II-III A072201 Glioblastoma, Recurrent, Block vs SOC ALLIANCE 03SEP2024:00:00:00   7   0.5  
    NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE NRG 12AUG2022:00:00:00   4   0.2  
    NRGHN006 HN, Erly Stg, Biopsy vs Dissection NRG 08JUL2020:00:00:00   8   0.3  
    NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN NRG 27OCT2021:00:00:00   19   0.0  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   8   0.0  
  III A092205 HN Squamous, Rec/Metas, Pem vs Pem+Cet ALLIANCE 21NOV2024:00:00:00   1   0.0  
    CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx CCTG 29SEP2022:00:00:00   1   0.0  
    CE7 Brain, 5+ Metastases, Radiosurg/Radiotherapy CCTG 25MAY2018:00:00:00   1   0.0  
    EA7222 Sarcoma, Poorly Diff, Dox+Pembro vs Dox ECOG-ACRIN 13JUN2024:00:00:00   21   1.2  
    NRG-GY035 Endometrial, TP53 Mut Adv/Recur, CP+-B+-P NRG 12JAN2026:00:00:00   1   0.2  
    NRG-GY037 Cervical, HiRisk LocalAdv, Pem+Chem NRG 29SEP2025:00:00:00   2   0.3  
    NRG-HN014 HN, Stg III/IV, Neoadj vs SOC NRG 20DEC2024:00:00:00   6   0.0  
    NRGBN003 Mening, Grd II, Observation vs Irradiation NRG 14JUN2017:00:00:00   3   0.0  
    NRGGY036 Ovary, All Stg, Olaparib +/- Bevac NRG 16JAN2025:00:00:00   5   0.2  
  OTHER A151804 irAEs, National Biorepository to Adv Studies ALLIANCE 31JAN2020:00:00:00   59   1.5  
PEOLC III S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 108 399 491 1.8 Nov-2030
    S2408 Panc Fistula Prevention, Lanreotide SWOG 14FEB2025:00:00:00   63 274   Mar-2026 Temp Close
PREV II EA2185 Panc, Impact of Panc Cyst Surveillance ECOG-ACRIN 16JAN2020:00:00:00   19   0.0  
  III NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs NRG 06OCT2021:00:00:00   235   13.3  
  OTHER A212102 Blind Ref Set for Multicancer Early Detection ALLIANCE 01AUG2022:00:00:00   332   4.8  
    NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO NRG 23JUN2020:00:00:00   17   0.3  
SXQOL II NRG-CC013 HN Squamous Cell, Rec Chemo, BMX NRG 16DEC2024:00:00:00   2   0.3  
  III A211901 Cancer survivors who smoke, txt cessation ALLIANCE 01DEC2021:00:00:00   19   0.3  
    NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction NRG 19SEP2022:00:00:00   21   1.0  
    NRGCC015 E-Mindfulness After Breast Cancer NRG 12JUN2025:00:00:00   16   2.3  
    S2205 ICE COMPRESS: Reduction of CIPN from Taxanes SWOG 16MAR2023:00:00:00 42 673 777 16.7 Mar-2027
  OTHER S2013 I-CHECKIT: ICI toxicity risk prediction study SWOG 16AUG2021:00:00:00 61 2640 3609 33.3 Feb-2029
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

20-SEP-2026 6:11

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase Comm. Int
grp		 Stat
Center		 Study NCIPROTO CA
Cntrl
Study		 Temp
Close
OTHER CCD     EAQ222CD CostCOM, Cancer Patients, OOP Cost Com   Y  
    Y COG ACCL16N1 Guideline Consistent Treatment AYA ALL ACCL16N1CD Y Y
    Y ALLIANCE A231602C Blood Cancer, Assess Financial Difficulty A231602CD Y Y
  ERLYTX Y ECOG-ACRIN EAY191 ComboMATCH EAY191 N  
  GI     A212101 Colorectal, New Dx. Gen Testing   Y  
  LEUK Y SWOG MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials MYELOMATCH N  
  LUNG Y SWOG LUNGMAP NSCLC, Adv, Master LUNGMAP N  
  OTHER Y ALLIANCE A151804 irAEs, National Biorepository to Adv Studies A151804 N  
  PREV Y ALLIANCE A212102 Blind Ref Set for Multicancer Early Detection A212102 Y  
    Y NRG NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO NRG-CC008 Y  
  SXQOL Y SWOG S2013 I-CHECKIT: ICI toxicity risk prediction study S2013 Y  
II BREAST Y NRG NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG-BR005 N Y
  ERLYTX N   21CTP.HN01 HN, Recur/Met, Amivantamab + Chemo   N  
    Y SWOG SN2426 cSCC, IC Met/Inop, Amivantamab v Cetuximab SN2426 N Y
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
  GI     EA2192 Panc, APOLLO   N  
    Y SWOG S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs S2104 N  
    Y CCTG CCTGNE1 Midgut NET, Unresect, 177 Lut vs Ever CCTG-NE1 Y  
  GU     A032102 Prostate, All Stg, Precision Diagnostics   Y  
    Y SWOG S2427 Blad, MIBC, RT + Pembrolizumab S2427 N  
    Y SWOG S2210 Pros, High Risk, BRCA, Neoadj Carbo S2210 N  
    Y ALLIANCE A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) A031702 N  
    Y NRG NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy NRG-GU012 N  
  LEUK N   21CTP.LEUK01 ALL, Ph+, Asciminib, Dasatinib and Prednisone   N  
        EA9213 T-ALL, dara-hyal for chemo refractory MRD   N  
    Y SWOG MM1OA-S04 MyeloMATCH: AML, ASTX727 + Ven (28D v 14D) MM1OA-S04 N  
    Y SWOG MM1OA-S03 AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena MM1OA-S03 N  
    Y SWOG MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental MM1YA-S01 N  
    Y ECOG-ACRIN MM1OA-EA02 MyeloMATCH: AML, New Dx, Ven+HMA MM1OA-EA02 N  
    Y ALLIANCE A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat A041703 N  
    Y CCTG MM1YA-CTG01 MyeloMATCH: AML, New Dx w/ Int Risk, Ven+Chem MM1YA-CTG01 N  
  LUNG Y SWOG S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu S1900G N  
    Y SWOG S1900K MET Exon 14: Tepotinib +/- Ramucirumab S1900K N  
    Y SWOG S1900N AGAs: SG alone, I alone, or SG + I S1900N N  
    Y SWOG S2409 ESCLC, Durvalumab +/- Biomarker Directed Tx S2409 N  
    Y SWOG S1900J MET Amplification: Amivantamab Hyaluronidase S1900J N  
    Y ECOG-ACRIN EA5162 NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 EA5162 N  
  LYMPH Y SWOG S2506 NHL, R/R MZL, Mozun +/- Zanu or Pola S2506 N  
    Y SWOG S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa S2207 Y  
    Y SWOG S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation S2114 N  
    Y ECOG-ACRIN EA4231 Lymph, DL B-Cell, Ven+Ib+Pred+Ob+Rev EA4231 N  
    Y ALLIANCE A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P A051902 N  
  MMYEL     A062102 MMYEL, All Stg, Iberdomide Tx   N  
    Y SWOG S2005 WM, Prev. Untreated, I/R or Z v V/R S2005 N  
    Y ECOG-ACRIN EAA173 MYEL, SMM, Rd +/- Daratumumab EAA173 Y  
  MULT Y SWOG S2101 Melan or HNSCC, Adv, Cabo + Nivo S2101 N  
  OTHER Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
    Y NRG NRGHN010 HER2+ SGC, T-DM1 vs TH NRG-HN010 N  
    Y NRG NRGGY032 Endo, ErlyStg Pole/p53, Adj Tx NRG-GY032 N  
    Y NRG NRG-HN015 ¿¿SquaCell HN, Rec/Enriched, NeoVsChemo¿ NRG-HN015 N  
    Y ECOG-ACRIN EA3191 HN, High Risk HNSCC, Adj +/- Pembro EA3191 N  
    Y ALLIANCE A092105 Nasopharyngeal, Adv, Niv/Ip +- Cab A092105 N  
  PREV Y ECOG-ACRIN EA2185 Panc, Impact of Panc Cyst Surveillance EA2185 Y  
  SXQOL Y NRG NRG-CC013 HN Squamous Cell, Rec Chemo, BMX NRG-CC013 Y  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N Y
  ERLYTX Y SWOG S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo S2012 N  
  GI     EA2234 Gastric, all stg, Pac+Sys vs Sys   N  
    Y SWOG S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo S2303 Y  
    Y ECOG-ACRIN EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab EA2174 N  
    Y NRG NRGGI008 Colon, Stg III, Adj Chemo NRG-GI008 N  
  GU     A032103 Urothelial, All Stg, MRD-Based Adj Tx   Y  
    Y ECOG-ACRIN EA8192 Blad, High Grade UTUC, Durv + Chemo EA8192 N  
  LUNG Y SWOG S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab S1800E N  
  OTHER Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y ALLIANCE A072201 Glioblastoma, Recurrent, Block vs SOC A072201 N  
    Y NRG NRGHN006 HN, Erly Stg, Biopsy vs Dissection NRG-HN006 Y  
    Y NRG NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN NRG-HN009 Y  
    Y NRG NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE NRG-GY026 Y  
III BREAST Y SWOG S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva S2206 Y  
    Y SWOG S2212 Breast, TNBC, Neoadj Chemo + Pembro S2212 Y  
    Y SWOG S2511 Brst, de novo StgIV oligo, locoreg tx vs SOC S2511 N  
    Y ALLIANCE A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib A011801 Y  
    Y ALLIANCE A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab A012103 Y  
    Y NRG NRGBR009 Breast, EarlyStg, Adjuvant Chemo NRG-BR009 Y  
    Y ALLIANCE A012303 Breast, HER2+, Shortened Adj A012303 Y  
  CCD Y SWOG S1703 Met Breast, STM-monitoring v Usual Care S1703 Y  
    Y SWOG S2424CD A-PACT vs SOC for GOC communication S2424CD Y  
    Y SWOG S2417CD Colrec Surv, Follow-up w/ CTAC site S2417CD Y  
    Y ALLIANCE A232402CD CCD, Dose Mod Algorithm for FOLFOX A232402CD Y  
  ERLYTX Y SWOG S2505 Sarcoma, Stg II-IIIB, Surg + Short vs Std RT S2505 N  
    Y COG AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo AGCT1532 Y Y
    Y COG AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult AGCT1531 Y  
    Y ECOG-ACRIN EA7211 Sarc, Hi-Risk RetroPeritoneal, Neo+Sur EA7211 N  
  GI     A022101 Colorectal, Metastatic, Ablative Tx   N  
    Y SWOG S2433 PANC, KRAS WT, Met, SOC Chemo +/- Panitumumab S2433 Y  
    Y CCTG CCTGCO32 Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad CCTG-CO32 Y  
    Y ECOG-ACRIN EA2222 Colorectal, Stg II-III, Hep Art Infusion EA2222 N  
    Y ALLIANCE A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo A022102 N  
  GU N   S2312 Pros, MCRPC, Cab +/- Carb   N  
    Y SWOG S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum S1802 Y  
    Y SWOG S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only S1931 N  
    Y SWOG S2419 Renal, adv clear cell, IO +/- Biotx, BIOFRONT S2419 N  
    Y ALLIANCE A032201 Renal Cell, High-Risk, Pembro+Tiv A032201 Y  
    Y NRG NRGGU013 Prostate, High-Risk, Five Fraction Radiation NRG-GU013 Y  
    Y CCTG CCTG-PR24 Prostate, Unfav, Stereo vs Brachy CCTG-PR24 Y  
    Y NRG NRG-GU015 Bladder, Muscle Invasive, Rad+Chem NRG-GU015    
    Y ECOG-ACRIN EA8231 Urothelial, Anti-PD(L)1, Pembro+Sac EA8231 Y  
    Y ECOG-ACRIN EA8191 Pros, Local vs Systemic Thrpy EA8191 Y  
    Y ALLIANCE A032303 Bladder, High Grade, Gem+BCG vs BCG A032303 N  
    Y ALLIANCE A032302 Prostate, Cast-Sens, Docetaxel A032302 Y  
    Y ALLIANCE A032304 Prostate, Meta CRPC w/Lu, Radioligand Effic A032304 Y  
    Y CCTG CCTG-PR26 Prostate, Cast Sensitive, Docetax CCTG-PR26 N  
  LEUK Y SWOG S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O S1925 Y  
    Y SWOG S2504 Richter Trans., Untreated, R-CHOP +/- Pirto S2504 Y  
    Y ALLIANCE A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo A041501 N  
  LUNG     EA5221 Lung, Advanced NSCLC, ChemoImmuno/Immuno   Y  
    Y SWOG S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance S2414 Y  
    Y NRG NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo NRG-LU008 Y  
    Y ALLIANCE A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO A081801 Y  
    Y ECOG-ACRIN EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 EA5182 N  
  LYMPH Y SWOG S2308 FL, LTB, Mosunetuzumab vs Rituximab S2308 N  
    Y ALLIANCE A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub A052101 Y  
    Y ECOG-ACRIN EA4232 Lymph, Peri T Cell, Auto Stem EA4232 N  
    Y COG AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy AHOD2131 Y  
    Y ALLIANCE A042302 CLL/SLL, Untreated Older, Zan+Son A042302 Y  
  MELAN Y ECOG-ACRIN EA6244 Melanoma, Naive Primary, Mgmt of Tx EA6244 Y  
  MMYEL Y SWOG S1803 MM, Maintenance, Len vs Len/Dara S1803 Y  
    Y SWOG S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D S2209 Y  
    Y SWOG S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT S2213 Y  
    Y ECOG-ACRIN EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) EAA181 Y  
  OTHER     CE7 Brain, 5+ Metastases, Radiosurg/Radiotherapy   Y  
    Y NRG NRGGY036 Ovary, All Stg, Olaparib +/- Bevac NRG-GY036 N  
    Y NRG NRGBN003 Mening, Grd II, Observation vs Irradiation NRG-BN003 Y  
    Y CCTG CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx CCTG-HN11 Y  
    Y ALLIANCE A092205 HN Squamous, Rec/Metas, Pem vs Pem+Cet A092205 Y  
    Y NRG NRG-HN014 HN, Stg III/IV, Neoadj vs SOC NRG-HN014 Y  
    Y NRG NRG-GY035 Endometrial, TP53 Mut Adv/Recur, CP+-B+-P NRG-GY035 N  
    Y ECOG-ACRIN EA7222 Sarcoma, Poorly Diff, Dox+Pembro vs Dox EA7222 N  
    Y NRG NRG-GY037 Cervical, HiRisk LocalAdv, Pem+Chem NRG-GY037 N  
  PEOLC Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y SWOG S2408 Panc Fistula Prevention, Lanreotide S2408 Y Y
  PREV Y NRG NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs NRG-CC005 Y  
  SXQOL     NRGCC015 E-Mindfulness After Breast Cancer   Y  
    Y SWOG S2205 ICE COMPRESS: Reduction of CIPN from Taxanes S2205 Y  
    Y ALLIANCE A211901 Cancer survivors who smoke, txt cessation A211901 Y  
    Y NRG NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction NRG-CC010 Y  

20-SEP-2026 6:11

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

Protocol
Number		 Study Accrual
Goal		 Open
Stat/Date		 Months
Open		 Accrual
as of
01Jan02		 Current Accrual Proj.
Annual
Accr.
Rate		 EXPCLOSE Proj.
Study
Duration
(Years)
S1501 S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol (PEOLC) 491 Y-09/15/17 108 399 399 22 Nov-2030 13.2
S1703 S1703 Met Breast, STM-monitoring v Usual Care (CCD) 498 Y-07/16/18 98 476 476 46 Feb-2027 8.6
S1800E S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab (LUNG) 378 Y-04/28/25 16 136 136 130 Jul-2028 3.2
S1802 S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum (GU) 1273 Y-09/17/18 96 1051 1051 88 Mar-2029 10.5
S1803 S1803 MM, Maintenance, Len vs Len/Dara (MMYEL) 1100 Y-06/27/19 86 1338 1338 0 000-0000 > 15 Yrs
S1925 S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O (LEUK) 247 Y-12/14/20 69 209 209 62 Apr-2027 6.4
S1931 S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only (GU) 336 Y-11/16/20 70 161 161 28 Nov-2032 12.0
S2012 S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo (ERLYTX) 189 Y-12/02/21 57 167 167 42 Mar-2027 5.3
S2205 S2205 ICE COMPRESS: Reduction of CIPN from Taxanes (SXQOL) 777 Y-03/16/23 42 673 673 200 Mar-2027 4.0
S2206 S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva (BREAST) 960 Y-10/30/23 34 414 414 154 Mar-2030 6.4
S2209 S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D (MMYEL) 510 Y-05/30/23 39 146 146 54 May-2033 10.0
S2212 S2212 Breast, TNBC, Neoadj Chemo + Pembro (BREAST) 2400 Y-07/21/23 37 1682 1682 864 Jun-2027 3.9
S2213 S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT (MMYEL) 142 Y-12/01/23 33 52 52 26 Feb-2030 6.2
S2303 S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo (GI) 224 Y-05/06/24 28 117 117 60 Jun-2028 4.1
S2308 S2308 FL, LTB, Mosunetuzumab vs Rituximab (LYMPH) 600 Y-08/01/24 25 423 423 288 Apr-2027 2.7
S2312 Pros, MCRPC, Cab +/- Carb (GU) 500 Y-09/03/24 24 71 71 52 Nov-2034 10.2
S2408 S2408 Panc Fistula Prevention, Lanreotide (PEOLC) 274 T-02/14/25 19 63 63 0 > 15 Yrs > 15 Yrs
S2414 S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance (LUNG) 306 Y-03/14/25 18 14 14 14 > 15 Yrs > 15 Yrs
S2417CD S2417CD Colrec Surv, Follow-up w/ CTAC site (CCD) 654 Y-08/04/25 13 126 126 156 Jan-2030 4.5
S2419 S2419 Renal, adv clear cell, IO +/- Biotx, BIOFRONT (GU) 718 Y-04/22/26 4 27 27 65.536587 Mar-2037 10.9
S2424CD S2424CD A-PACT vs SOC for GOC communication (CCD) 1000 Y-06/01/26 3 4 4 13.255191 > 15 Yrs > 15 Yrs
S2433 S2433 PANC, KRAS WT, Met, SOC Chemo +/- Panitumumab (GI) 94 Y-12/26/25 8 1 1 2 > 15 Yrs > 15 Yrs
S2504 S2504 Richter Trans., Untreated, R-CHOP +/- Pirto (LEUK) 102 Y-06/01/26 3 1 1 3.3137978 > 15 Yrs > 15 Yrs
S2505 S2505 Sarcoma, Stg II-IIIB, Surg + Short vs Std RT (ERLYTX) 296 Y-07/06/26 2 0 0      
S2511 S2511 Brst, de novo StgIV oligo, locoreg tx vs SOC (BREAST) 534 Y-08/18/26 1 0 0      
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.